Intact Investment Management Inc. Has $13.49 Million Position in Johnson & Johnson (NYSE:JNJ)

Intact Investment Management Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 31.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 87,000 shares of the company’s stock after purchasing an additional 21,000 shares during the period. Intact Investment Management Inc.’s holdings in Johnson & Johnson were worth $13,485,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in Johnson & Johnson by 1.4% in the 1st quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock valued at $31,231,193,000 after acquiring an additional 2,688,798 shares in the last quarter. Moneta Group Investment Advisors LLC raised its holdings in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC raised its holdings in Johnson & Johnson by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after acquiring an additional 294,671 shares in the last quarter. Morgan Stanley raised its holdings in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares in the last quarter. 68.40% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Credit Suisse Group boosted their price target on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Barclays lowered their price target on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a report on Friday. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Thursday, August 31st. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $170.65.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is owned by insiders.

Johnson & Johnson Stock Up 0.3 %

Shares of NYSE:JNJ opened at $160.56 on Friday. The business’s 50-day moving average is $166.11 and its 200-day moving average is $161.50. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The company has a market capitalization of $417.29 billion, a price-to-earnings ratio of 32.50, a P/E/G ratio of 3.47 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.59 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.03 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.